MX2022006214A - Composiciones y métodos para desreprimir genes diana del factor de transcripción silenciador de re1. - Google Patents

Composiciones y métodos para desreprimir genes diana del factor de transcripción silenciador de re1.

Info

Publication number
MX2022006214A
MX2022006214A MX2022006214A MX2022006214A MX2022006214A MX 2022006214 A MX2022006214 A MX 2022006214A MX 2022006214 A MX2022006214 A MX 2022006214A MX 2022006214 A MX2022006214 A MX 2022006214A MX 2022006214 A MX2022006214 A MX 2022006214A
Authority
MX
Mexico
Prior art keywords
seq
derepressing
compositions
methods
transcription factor
Prior art date
Application number
MX2022006214A
Other languages
English (en)
Inventor
Edmund Nesti
Alexander Pisarchik
Original Assignee
Alcamena Stem Cell Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcamena Stem Cell Therapeutics Llc filed Critical Alcamena Stem Cell Therapeutics Llc
Publication of MX2022006214A publication Critical patent/MX2022006214A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03016—Phosphoprotein phosphatase (3.1.3.16), i.e. calcineurin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La invención se proporciona compuestos, composiciones y métodos para desreprimir genes diana del factor de transcripción silenciador de RE1 (REST). En particular, se describe un péptido que tiene la secuencia TEDLEPPEPPLPKEN (SEQ. ID NO: 1) y EDLEPPEPPLPK (SEQ. ID NO: 15), o las secuencias inversas compuestas de los D-aminoácidos (retroinvertidos, RI) nekplppeppeldet (SEQ ID NO: 16) y kplppeppelde (SEQ ID NO: 17), para inhibir la actividad de REST. Los péptidos son útiles para tratar, prevenir o mejorar padecimientos tales como traumatismo craneoencefálico, epilepsia, demencia, enfermedad de Huntington (HD), dolor crónico, cáncer cerebral (incluido el glioblastoma multiforme), cáncer pancreático, diabetes y lesión del nervio periférico.
MX2022006214A 2019-11-22 2020-11-20 Composiciones y métodos para desreprimir genes diana del factor de transcripción silenciador de re1. MX2022006214A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962939149P 2019-11-22 2019-11-22
US202063086248P 2020-10-01 2020-10-01
PCT/US2020/061632 WO2021102345A1 (en) 2019-11-22 2020-11-20 Compositions and methods for derepressing re1 silencing transcription factor target genes

Publications (1)

Publication Number Publication Date
MX2022006214A true MX2022006214A (es) 2022-06-22

Family

ID=75981713

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022006214A MX2022006214A (es) 2019-11-22 2020-11-20 Composiciones y métodos para desreprimir genes diana del factor de transcripción silenciador de re1.

Country Status (11)

Country Link
US (1) US20230059411A1 (es)
EP (1) EP4061833A4 (es)
JP (1) JP2023503920A (es)
KR (1) KR20220104008A (es)
CN (1) CN115023434A (es)
AU (1) AU2020386637A1 (es)
BR (1) BR112022009898A2 (es)
CA (1) CA3162241A1 (es)
IL (1) IL293165A (es)
MX (1) MX2022006214A (es)
WO (1) WO2021102345A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115887655A (zh) * 2021-09-30 2023-04-04 中国科学院脑科学与智能技术卓越创新中心 直接转分化治疗神经系统疾病
CN114377000A (zh) * 2021-12-24 2022-04-22 中山大学孙逸仙纪念医院 普瑞巴林在制备用于预防或治疗放射性脑损伤药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2019A (en) 1841-03-29 goedes
WO2010129023A2 (en) * 2009-04-28 2010-11-11 President And Fellows Of Harvard College Supercharged proteins for cell penetration
US20120070419A1 (en) * 2010-03-25 2012-03-22 International Stem Cell Corporation Method of altering the differentiative state of a cell and compositions thereof
US20150299698A1 (en) 2012-11-01 2015-10-22 The Regents Of The University Of California Methods for engineering non-neuronal cells into neurons and using newly engineered neurons to treat neurodegenerative diseases
WO2016019315A2 (en) 2014-08-01 2016-02-04 Oregon Health & Science University Methods and compositions useful in manipulating the stability of re1 silencing transcription factor

Also Published As

Publication number Publication date
US20230059411A1 (en) 2023-02-23
BR112022009898A2 (pt) 2022-09-06
JP2023503920A (ja) 2023-02-01
KR20220104008A (ko) 2022-07-25
EP4061833A1 (en) 2022-09-28
IL293165A (en) 2022-07-01
CA3162241A1 (en) 2021-05-14
AU2020386637A1 (en) 2022-06-16
WO2021102345A1 (en) 2021-05-27
EP4061833A4 (en) 2023-09-06
CN115023434A (zh) 2022-09-06

Similar Documents

Publication Publication Date Title
MX2022006214A (es) Composiciones y métodos para desreprimir genes diana del factor de transcripción silenciador de re1.
NZ587105A (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
MX2008009493A (es) Peptido novedoso y uso del mismo.
MX359516B (es) Composiciones y metodos para prevenir o tratar enfermedades, afecciones, o procesos caracterizados por la proliferacion abrellante de fibro blasto y deposicion de matriz extracelular.
EA201171451A1 (ru) Генетические маркеры, ассоциированные с ответом на интерферон-альфа
NZ733882A (en) Compositions for modulating c9orf72 expression
TW201712023A (en) Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups
MX358603B (es) Tratamiento de enfermedades relacionadas con un gen supresor de tumor mediante inhibicion del transcrito antisentido natural para el gen.
MX339820B (es) Compuestos oligonucleottidos designados para inhibir el transcrito antisentido natrual apra apolipoproteina-a1.
TW200744642A (en) Novel peptides for use in the treatment of obesity
ITMI20021527A1 (it) Anticorpi anti componente c5 del complemento e loro uso
MX359953B (es) Ácido nucleico que comprende o que codifica un tallo-rizo de histona y una secuencia poli (a) o una señal de poliadenilación para incrementar la expresión de una proteína terapéutica codificada.
WO2006108718B1 (en) Micro rna
WO2003002596A3 (en) Use of dipeptidyl peptidase iv inhibitors as therapeutics for neurological disorders
RU2017145051A (ru) Внеклеточная днк в качестве терапевтической мишени при нейродегенерации
WO2006048452A3 (en) Peptides for use in treating of obesity
EP3747457A3 (en) Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases
MX2017006372A (es) Composiciones y metodos para prevenir o tratar enfermedades, condiciones o procesos caracterizados por proliferacion de fibroblasto aberrante y matrix extracelular.
WO2019045248A3 (ko) 주름 개선 활성을 나타내는 펩타이드 및 이의 용도
MX2022004759A (es) Métodos y composiciones para tratar enfermedades y trastornos hepáticos.
WO2013173827A3 (en) Methods and compositions for inhibiting diseases of the central nervous system
ATE307886T1 (de) Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung
MX2011013972A (es) Peptido novedoso y su uso.
CA2634902A1 (en) Anticancer agent comprising a peptide
JP2013535965A5 (es)